Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • bayer

    Tag: bayer

    You Searched For "bayer"
    Bayer and Curadev sign research collaboration and license agreement for STING antagonists

    Bayer and Curadev sign research collaboration and license agreement for STING antagonists

    Medical Dialogues Bureau25 March 2020 5:45 AM GMT
    Berlin & New Delhi: Bayer and Curadev Pvt. Ltd., a drug discovery company based in India, has announced a research collaboration and license...
    Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

    Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

    Medical Dialogues Bureau25 Nov 2019 3:30 AM GMT
    Median overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
    Bayer Roundup suits increase to 42700

    Bayer Roundup suits increase to 42700

    Medical Dialogues Bureau1 Nov 2019 3:30 AM GMT
    A court-appointed mediator between Bayer and US plaintiffs in August denied reports the company had offered an $8 billion settlement to get the cases...
    Bayer disagrees with German Government decision to ban Glyphosate from end of 2023

    Bayer disagrees with German Government decision to ban Glyphosate from end of 2023

    Medical Dialogues Bureau6 Sep 2019 3:30 AM GMT
    "Such a ban would ignore the overwhelming scientific assessments of competent authorities around the world that have determined for more than 40 years...
    Former JnJ executive Marianne De Backer to lead Bayer pharma division

    Former JnJ executive Marianne De Backer to lead Bayer pharma division

    Medical Dialogues Bureau4 Sep 2019 4:00 AM GMT
    Marianne De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival JnJ,...
    Bayer sells Animal Health unit to US drug firm Elanco for USD 7.6 billion

    Bayer sells Animal Health unit to US drug firm Elanco for USD 7.6 billion

    Medical Dialogues Bureau21 Aug 2019 3:30 AM GMT
    Bayer said in a statement that the sale, aimed at sharpening the company's focus on life sciences, was expected to be concluded in mid-2020 pending...
    Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month

    Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month

    Medical Dialogues Bureau17 Aug 2019 3:45 AM GMT
    Rozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies...
    Bayer buys BlueRock in USD 600 million bet on stem cell therapies

    Bayer buys BlueRock in USD 600 million bet on stem cell therapies

    Medical Dialogues Bureau9 Aug 2019 3:30 AM GMT
    FRANKFURT: German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up...
    Bayer Rivaroxaban tablets win CDSCO Committee nod for waiver of local clinical trial; directed to carry Phase IV trial

    Bayer Rivaroxaban tablets win CDSCO Committee nod for waiver of local clinical trial; directed to carry Phase IV trial

    Medical Dialogues Bureau8 Aug 2019 11:58 AM GMT
    New Delhi: The apex drug regulatory body, Central Drugs Standard Control Organisation's (CDSCO) Technical Committee has recommended for grant of...
    Cancer Drug Patent Issues: Delhi HC junks Bayer plea to block Natco Pharma Regonat

    Cancer Drug Patent Issues: Delhi HC junks Bayer plea to block Natco Pharma Regonat

    Farhat Nasim15 July 2019 9:22 AM GMT
    New Delhi: The Delhi High Court recently junked the injunction petition filed by the German Drugmaker to restrain the Hyderabad-based Natco Pharma...
    GSK offers concessions to address Pfizer deal concerns

    GSK offers concessions to address Pfizer deal concerns

    Farhat Nasim23 Jun 2019 3:29 AM GMT
    GSK announced the deal in December last year, a move which will put it ahead of rivals Johnson & Johnson, Bayer and Sanofi.BRUSSELS:...
    GSK forms drug discovery alliance with University of California CRISPR researchers

    GSK forms drug discovery alliance with University of California CRISPR researchers

    Medical Dialogues Bureau14 Jun 2019 6:54 AM GMT
    British drugmaker GSK said it has struck a research deal with the early pioneers of a prominent gene-editing technology at the University of...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok